Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only conditioning regimen. Low incidence of failed engraftment and severe acute GVHD

Bone Marrow Transplantation

Volumn 17, Issue 4, 1996, Pages 549-554

  Topolsky, D ^a   Crilley, P ^a   Styler, M J ^a   Bulova, S ^a   Brodsky, I ^a   Marks, D I ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

Chemotherapy conditioning; Older patient; Unrelated BMT

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; METHOTREXATE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG FATALITY; FEMALE; GENOTYPE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL; TASK PERFORMANCE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN OCCLUSION; WORK;

ACTUARIAL ANALYSIS; ACUTE DISEASE; ADULT; ANTI-INFECTIVE AGENTS; BONE MARROW TRANSPLANTATION; BUSULFAN; CAUSE OF DEATH; CRITICAL CARE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEPATIC VENO-OCCLUSIVE DISEASE; HISTOCOMPATIBILITY; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LYMPHOCYTE DEPLETION; MALE; METHOTREXATE; MIDDLE AGED; RISK; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0029919555     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kernan NA, Bartsch G, Ash RC et al. Retrospective analysis of 462 unrelated marrow transplants facilitated by the National Marrow Donor Program (NMDP) for treatment of acquired and congenital disorders of the lymphohematopoietic system and congenital metabolic disorders. New Engl J Med 1993; 328: 593-602.
2. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993; 119: 207-214.
3. Drobyski WR, Ash RC, Casper JT et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free surival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980-1987.
4. Ash RC, Casper JT, Chitambar RC et al. Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors. New Engl J Med 1990; 322: 485-494.
5. Anasetti C, Hansen JA. Bone marrow transplantation from HLA-partially matched related donors and unrelated volunteer donors. In Forman SJ et al (eds). Bane Marrow Transplantation. Blackwell Scientific Publications: Boston, 1994, pp 665-680.
6. Devine S, Mauer D, Geller RB. Unrelated-donor ABMT: clinical update. Contemp Oncol 1994: 13-22.
7. Clift RA, Buckner CD. Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
8. Sahebi F, Bolwell B, Crilley P et al. Unrelated allogeneic bone marrow transplantation using high dose busulfan and cyclophosphamide (Bu-Cy) conditioning regimen. Blood 1993; 82: 81 (Abstract 314).
9. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new bulsulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
10. Spencer A, Szydlo RM, van Rhee F et al. Volunteer unrelated donor BMT for chronic myeloid leukaemia; report on 118 patients from a single institution. Bone Marrow Transplant 1995; 15: S2 (Abstract 37).
11. Nevill TJ, Barnett MJ, Klingemann H-G et al. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224-1232.
12. Goldman JM, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. New Engl J Med 1986; 314: 202-207.
13. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
14. Biggs JC, Szer J, Crilley P et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation with BuCy2. Blood 1992; 80: 1352-1357.
15. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-204.
16. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122.
17. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
18. Marks DI, Hughes TP, Szydlo R et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of graft-versus-host disease prophylaxis on survival. Br J Haematol 1992; 81: 383-390.
19. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic bone marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
20. Neumanitis J, Anasetti C, Storb R et al. Phase II trial of recombinant human GM-CSF in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 1992; 79: 2572-2577.
21. Ratanatharathorn V, Karanes C, Momin F et al. Preparative regimens with total body irradiation (TBI) in the recipients of unrelated donor marrow. Blood 1994; 84: 342a (Abstract 1352).
22. Anasetti C, Amos D, Beatty P et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma, New Engl J Med 1989; 320: 197-204.
23. Weisdorf DJ, Verfaillie CM, Davies SM et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 1995; 85: 3452-3456.
24. Ringden O, Horowitz MM, Gale RP et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. J Am Med Assoc 1993; 270: 57-60.
25. Rapoport AP, DiPersio JF, Martin BA et al. Patients >40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients age <40 years. Bone Marrow Transplant 1995; 15: 523-530.
26. Al-Daccak R, Loiseau P, Rabian C et al. HLA-DR, DQ, and/or DP genotypic mismatches between recipient - donor pairs in unrelated bone marrow transplantation and transplant clinical outcome. Transplantation 1990; 50: 960-964.
27. Lanino E, Anasetti C, Longton G et al. Prevention of cytomegalovirus disease with ganciclovir in recipients of marrow transplants from unrelated donors. Blood 1993; 82: 344a (Abstract 1359).